These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32725783)

  • 1. First Clinical Study with AP30663 - a K
    Gal P; Klaassen ES; Bergmann KR; Saghari M; Burggraaf J; Kemme MJB; Sylvest C; Sørensen U; Bentzen BH; Grunnet M; Diness JG; Edvardsson N
    Clin Transl Sci; 2020 Nov; 13(6):1336-1344. PubMed ID: 32725783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 trial of AP30663, a K
    Yfanti C; Vestbjerg B; Van't Westende J; Edvardsson N; Monfort LM; Olesen MS; Bentzen BH; Grunnet M; Eveleens Maarse BC; Diness JG; Kemme MJB; Sørensen U; Moerland M; van Esdonk MJ; Klaassen ES; Gal P; Holst AG
    Br J Clin Pharmacol; 2024 Apr; 90(4):1027-1035. PubMed ID: 37990600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the K
    Holst AG; Tomcsányi J; Vestbjerg B; Grunnet M; Sørensen US; Diness JG; Bentzen BH; Edvardsson N; Hohnloser SH; Bhatt DL; Dorian P
    Nat Med; 2024 Jan; 30(1):106-111. PubMed ID: 38092897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The K
    Diness JG; Kirchhoff JE; Speerschneider T; Abildgaard L; Edvardsson N; Sørensen US; Grunnet M; Bentzen BH
    Front Pharmacol; 2020; 11():159. PubMed ID: 32180722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter.
    Mao Z; Wheeler JJ; Townsend R; Gao Y; Kshirsagar S; Keirns JJ
    J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):541-62. PubMed ID: 21786177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009.
    Crijns HJ; Van Gelder IC; Walfridsson H; Kulakowski P; Rónaszéki A; Dedek V; Malm A; Almgren O
    Heart Rhythm; 2006 Nov; 3(11):1321-31. PubMed ID: 17074639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological cardioversion of atrial fibrillation--a double-blind, randomized, placebo-controlled, multicentre, dose-escalation study of AZD1305 given intravenously.
    Rónaszéki A; Alings M; Egstrup K; Gaciong Z; Hranai M; Király C; Sereg M; Figatowski W; Bondarov P; Johansson S; Frison L; Edvardsson N; Berggren A
    Europace; 2011 Aug; 13(8):1148-56. PubMed ID: 21561900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
    Beatch GN; Mangal B
    BMC Cardiovasc Disord; 2016 May; 16():113. PubMed ID: 27233239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man.
    Bentzen BH; Bomholtz SH; Simó-Vicens R; Folkersen L; Abildgaard L; Speerschneider T; Muthukumarasamy KM; Edvardsson N; Sørensen US; Grunnet M; Diness JG
    Front Pharmacol; 2020; 11():610. PubMed ID: 32477117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
    Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
    Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial.
    Hornestam B; Jerling M; Karlsson MO; Held P;
    Eur J Clin Pharmacol; 2003 Mar; 58(11):747-55. PubMed ID: 12634981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study.
    Ellenbogen KA; Stambler BS; Wood MA; Sager PT; Wesley RC; Meissner MC; Zoble RG; Wakefield LK; Perry KT; Vanderlugt JT
    J Am Coll Cardiol; 1996 Jul; 28(1):130-6. PubMed ID: 8752805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR.
    Piccini JP; Pritchett EL; Davison BA; Cotter G; Wiener LE; Koch G; Feld G; Waldo A; van Gelder IC; Camm AJ; Kowey PR; Iwashita J; Dittrich HC
    Heart Rhythm; 2016 Sep; 13(9):1777-83. PubMed ID: 27108936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion.
    Kochiadakis GE; Igoumenidis NE; Solomou MC; Parthenakis FI; Christakis-Hampsas MG; Chlouverakis GI; Tsatsakis AM; Vardas PE
    Cardiovasc Drugs Ther; 1998 Mar; 12(1):75-81. PubMed ID: 9607135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF Study).
    Maciag A; Farkowski MM; Chwyczko T; Beckowski M; Syska P; Kowalik I; Pytkowski M; Wozniak J; Dabrowski R; Szwed H
    Europace; 2017 Oct; 19(10):1637-1642. PubMed ID: 28339554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.
    Roy D; Rowe BH; Stiell IG; Coutu B; Ip JH; Phaneuf D; Lee J; Vidaillet H; Dickinson G; Grant S; Ezrin AM; Beatch GN;
    J Am Coll Cardiol; 2004 Dec; 44(12):2355-61. PubMed ID: 15607398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo.
    Jordaens L; Trouerbach J; Calle P; Tavernier R; Derycke E; Vertongen P; Bergez B; Vandekerckhove Y
    Eur Heart J; 1997 Apr; 18(4):643-8. PubMed ID: 9129896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study.
    Bianconi L; Castro A; Dinelli M; Alboni P; Pappalardo A; Richiardi E; Santini M
    Eur Heart J; 2000 Aug; 21(15):1265-73. PubMed ID: 10924317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
    Nørgaard BL; Wachtell K; Christensen PD; Madsen B; Johansen JB; Christiansen EH; Graff O; Simonsen EH
    Am Heart J; 1999 Jun; 137(6):1062-9. PubMed ID: 10347332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation.
    Ford J; Milnes J; El Haou S; Wettwer E; Loose S; Matschke K; Tyl B; Round P; Ravens U
    Heart Rhythm; 2016 Feb; 13(2):555-64. PubMed ID: 26455450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.